查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2022530

普拉德-威利症候群（PWS）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

Prader-Willi Syndrome (PWS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3个工作天内

价格
简介目录

普拉德-威利症候群（PWS）概述

Prader-Willi 症候群 (PWS) 是一种罕见的、复杂的、多系统疾病，由位于 15 号染色体 q11.2–q13 区域的父系遗传印记基因表达缺失引起。这种基因缺失主要由父系缺失或母系单基因二倍体引起，导致严重的下视丘功能障碍，这是此疾病表型的核心因素。

临床上，普拉德-威利症候群（PWS）的病程呈现明显的双相性。新生儿期，其特征为严重的中枢性肌张力低下、饮食障碍和发育不良。到了婴儿早期，病情会发展为病理性过度餵养，表现为饱腹感信号受损和持续不断的进食行为。若不进行积极干预，可导致迅速的肥胖和继发性代谢併发症，包括第2型糖尿病和严重的阻塞型睡眠呼吸中止症呼吸中止症候群。

除了代谢负担外，普拉德-威利症候群（PWS）还伴随多种神经行为和内分泌症状，包括轻度至中度智能障碍、强迫症、情绪失调、性腺功能减退和中枢性生长激素缺乏。此病的治疗仍需大量资源和多学科协作。早期启动重组人体生长荷尔蒙（rhGH）治疗是治疗的关键，可改善身高成长、身体组成和代谢指标。然而，目前尚无核准的治疗方法过度进食的方法，仍是此病最亟待解决的问题。因此，长期疾病管理主要依赖严格的环境措施（例如饮食限制）和持续的看护者监督。

主要亮点：

  • PWS 是一种罕见的、终身性的多系统疾病，由下视丘功能障碍引起。虽然美国确诊患者的数量保持稳定，但正在逐渐增加。
  • 由于诊断技术的进步和生存时间的延长，预计美国患有该疾病的人数将从 2025 年的 13,900 人增加到 2035 年的 14,800 人，呈现渐进增长的趋势（年复合增长率为 0.6%–0.7%）。
  • 这种疾病的特征是严重的过度进食和肥胖相关併发症，由于缺乏核准的标靶治疗，因此成为最重要的未满足需求。
  • 鑑于临床上对以食慾调节和下视丘路径为标靶的治疗方法的关注度日益提高，未来的治疗模式预计将发生重大变化。

市场概况：

  • 美国普瑞德威利症候群 (PWS) 市场预计将从 2025 年的 5.59 亿美元增长到 2035 年的 39.6 亿美元，反映出强劲的两位数复合年增长率，这主要得益于针对神经性贪食症的后期开发疗法的推动。
  • 目前市场收入主要由重组人体生长荷尔蒙(rhGH) 疗法驱动，该疗法可解决生长和代谢问题，但无法解决贪食症。
  • 未来市场扩张将很大程度上取决于针对食慾失调和改善长期疾病结果的治疗方法的商业化成功。

格式化和更新讯息

  • 详细报告（PDF）
  • 市场预测模型（基于微软Excel）
  • 流行病学数据（MS Excel，互动式工具）
  • 高阶主管洞察（PPT简报）
  • 其他功能：定期更新、自订和顾问支援。
  • 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

  • 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
  • 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
  • 未来十年市场收入和病患份额的预测是多少？
  • 哪些因素对市场趋势影响最大？
  • 受访专家对目前和新兴的治疗方法有何看法？
  • 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
  • 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
  • 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

  • G8
    • 我们
    • EU5
      • 法国
      • 德国
      • 义大利
      • 西班牙
      • 英国
    • 日本
    • 中国

大公司

  • Harmony Biosciences Management, Inc.
  • ConSynance Therapeutics
  • Soleno Therapeutics, Inc.
  • Bright Minds Biosciences Pty Ltd
  • Aardvark Therapeutics, Inc.
  • Pfizer
  • Rhythm Pharmaceuticals, Inc.

目录

第一章：主要调查结果及分析师说明

  • 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

  • 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

  • 重点
  • 发病率/盛行率
  • 已确诊并接受药物治疗的患者人数
  • 合併症
  • 其他相关患者群

第四章 市场规模及预测

  • 重点
  • 市场驱动因素与限制因素
  • 按药物类别分類的趋势
  • 各国具体趋势

第五章 竞争情势

  • 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
  • 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期研发管线

第六章：未满足的需求与目标产品分析

  • 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
  • TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

简介目录

Prader-Willi Syndrome (PWS) Market Outlook

Thelansis's "Prader-Willi Syndrome (PWS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prader-Willi Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Prader-Willi Syndrome (PWS) Overview

Prader-Willi Syndrome (PWS) is a rare, complex, multisystem disorder driven by loss of expression of paternally inherited imprinted genes on chromosome 15q11.2-q13. This genetic defect most commonly arises from a paternal deletion or maternal uniparental disomy, leading to profound hypothalamic dysfunction-the central driver of the disease phenotype.

Clinically, PWS follows a well-defined biphasic trajectory. The neonatal phase is marked by severe central hypotonia, poor feeding, and failure to thrive. This transitions in early childhood to pathologic hyperphagia, characterized by impaired satiety signaling and relentless food-seeking behavior. Without strict intervention, this results in rapid-onset obesity and downstream metabolic complications, including Type 2 Diabetes and severe Obstructive Sleep Apnea.

Beyond metabolic burden, PWS presents with a broad neurobehavioral and endocrine spectrum, including mild-to-moderate intellectual disability, compulsive behaviors, emotional dysregulation, hypogonadism, and central growth hormone deficiency. Management remains highly resource-intensive and multidisciplinary. Early initiation of recombinant human growth hormone (rhGH) therapy is the cornerstone of care, demonstrating benefits in linear growth, body composition, and metabolic parameters. However, there are no approved therapies targeting hyperphagia, which remains the most critical unmet need. As a result, long-term disease control depends heavily on stringent environmental measures (e.g., food security restrictions) and continuous caregiver supervision.

Key Highlights:

  • PWS is a rare, lifelong, multisystem disorder driven by hypothalamic dysfunction, with a stable but gradually increasing diagnosed patient population in the US.
  • The US prevalent population is estimated to grow from 13.9K in 2025 to 14.8K by 2035, reflecting a modest growth trajectory (0.6-0.7% CAGR) driven by improved diagnosis and survival.
  • The disease is characterized by severe hyperphagia and obesity-related complications, representing the most critical unmet need due to the absence of approved targeted therapies.
  • Increasing clinical focus on appetite-regulating and hypothalamic pathway-targeted therapies is expected to significantly transform the future treatment landscape.

Market Overview:

  • The US PWS market is projected to expand from $559M in 2025 to $3.96B by 2035, reflecting a strong double-digit CAGR, primarily driven by late-stage pipeline therapies targeting hyperphagia.
  • Current market revenues are largely supported by recombinant human growth hormone (rhGH) therapy, which addresses growth and metabolic aspects but not hyperphagia.
  • Future market expansion will be highly dependent on successful commercialization of therapies targeting appetite dysregulation and improving long-term disease outcomes.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Harmony Biosciences Management, Inc.
  • ConSynance Therapeutics
  • Soleno Therapeutics, Inc.
  • Bright Minds Biosciences Pty Ltd
  • Aardvark Therapeutics, Inc.
  • Pfizer
  • Rhythm Pharmaceuticals, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)